首页> 外文期刊>Nature >Chromatin-modifying enzymes as modulators of reprogramming
【24h】

Chromatin-modifying enzymes as modulators of reprogramming

机译:染色质修饰酶作为重编程调节剂

获取原文
获取原文并翻译 | 示例
       

摘要

Generation of induced pluripotent stem cells (iPSCs) by somatic cell reprogramming involves global epigenetic remodelling. Whereas several proteins are known to regulate chromatin marks associated with the distinct epigenetic states of cells before and after reprogramming, the role of specific chromatin-modifying enzymes in reprogramming remains to be determined. To address how chromatin-modifying proteins influence reprogramming, we used short hairpin RNAs (shRNAs) to target genes in DNA and histone methylation pathways, and identified positive and negative modulators of iPSC generation. Whereas inhibition of the core components of the polycomb repressive complex 1 and 2, including the histone 3 lysine 27 methyltransferase EZH2, reduced reprogramming efficiency, suppression of SUV39H1, YY1 and DOT1L enhanced reprogramming. Specifically, inhibition of the H3K79 histone methyltransferase DOT1L by shRNA or a small molecule accelerated reprogramming, significantly increased the yield of iPSC colonies, and substituted for KLF4 and c-Myc (also known as MYC). Inhibition of DOT1L early in the reprogramming process is associated with a marked increase in two alternative factors, NANOG and LIN28, which play essential functional roles in the enhancement of reprogramming. Genome-wide analysis of H3K79me2 distribution revealed that fibroblast-specific genes associated with the epithelial to mesenchymal transition lose H3K79me2 in the initial phases of reprogramming. DOT1L inhibition facilitates the loss of this mark from genes that are fated to be repressed in the pluripotent state. These findings implicate specific chromatin-modifying enzymes as barriers to or facilitators of reprogramming, and demonstrate how modulation of chromatin-modifying enzymes can be exploited to more efficiently generate iPSCs with fewer exogenous transcription factors.
机译:通过体细胞重编程产生诱导性多能干细胞(iPSC)涉及全球表观遗传重塑。尽管已知几种蛋白质可调节重编程前后细胞的不同表观遗传状态相关的染色质标记,但尚需确定特定染色质修饰酶在重编程中的作用。为了解决染色质修饰蛋白如何影响重编程,我们使用短发夹RNA(shRNA)靶向DNA和组蛋白甲基化途径中的基因,并鉴定了iPSC产生的正向和负向调节剂。抑制聚梳抑制复合物1和2的核心成分,包括组蛋白3赖氨酸27甲基转移酶EZH2,降低了重编程效率,抑制了SUV39H1,YY1和DOT1L增强了重编程。具体来说,shRNA或小分子对H3K79组蛋白甲基转移酶DOT1L的抑制作用加速了重编程,显着提高了iPSC集落的产量,并取代了KLF4和c-Myc(也称为MYC)。在重新编程过程的早期抑制DOT1L与两个替代因子(NANOG和LIN28)的显着增加有关,它们在增强重新编程中起着重要的功能作用。 H3K79me2分布的全基因组分析表明,与上皮到间质转化相关的成纤维细胞特异性基因在重编程的初始阶段丢失了H3K79me2。 DOT1L抑制促进了注定要在多能状态下被抑制的基因中该标记的丢失。这些发现暗示特定的染色质修饰酶是重编程的障碍或促进程序,并证明了如何利用染色质修饰酶的调节作用可以更有效地产生具有较少外源转录因子的iPSC。

著录项

  • 来源
    《Nature》 |2012年第7391期|p.598-602|共5页
  • 作者单位

    Stem Cell Transplantation Program,Division of Pediatric Hematology and Oncology,Manton Center for Orphan Disease Research,Children's Hospital Boston and Dana Farber Cancer Intitute,Boston,Massachusetts,02115,USA,Department of Biological Chemistry and Molecular Pharmacology,Harvard Medical School,Boston,Massachusetts,02115,USA,Harvard Stem Cell Institute,Cambridge,Massachusetts,02138,USA,Stem Cell Program,Children's Hospital Boston,Boston,Massachusetts,02115,USA;

    German Cancer Research Center,Heidelberg,69120,Germany;

    Stem Cell Transplantation Program,Division of Pediatric Hematology and Oncology,Manton Center for Orphan Disease Research,Children's Hospital Boston and Dana Farber Cancer Intitute,Boston,Massachusetts,02115,USA,Department of Biological Chemistry and Molecular Pharmacology,Harvard Medical School,Boston,Massachusetts,02115,USA,Harvard Stem Cell Institute,Cambridge,Massachusetts,02138,USA,Stem Cell Program,Children's Hospital Boston,Boston,Massachusetts,02115,USA;

    Division of Hematology/Oncology,Children's Hospital,Harvard Medical School,Boston,Massachusetts,02115,USA,Department of Pediatric Oncology,Harvard Medical School,Boston,Massachusetts,02115,USA;

    Harvard Stem Cell Institute,Cambridge,Massachusetts,02138,USA,Division of Hematology/Oncology,Children's Hospital,Harvard Medical School,Boston,Massachusetts,02115,USA,Department of Pediatric Oncology,Harvard Medical School,Boston,Massachusetts,02115,USA;

    Harvard Stem Cell Institute,Cambridge,Massachusetts,02138,USA,Division of Hematology/Oncology,Children's Hospital,Harvard Medical School,Boston,Massachusetts,02115,USA,Department of Pediatric Oncology,Harvard Medical School,Boston,Massachusetts,02115,USA;

    Stem Cell Transplantation Program,Division of Pediatric Hematology and Oncology,Manton Center for Orphan Disease Research,Children's Hospital Boston and Dana Farber Cancer Intitute,Boston,Massachusetts,02115,USA,Department of Biological Chemistry and Molecular Pharmacology,Harvard Medical School,Boston,Massachusetts,02115,USA,Harvard Stem Cell Institute,Cambridge,Massachusetts,02138,USA,Stem Cell Program,Children's Hospital Boston,Boston,Massachusetts,02115,USA;

    Department of Molecular Biology and Genetics,Bilkent University,Ankara,06800,Turkey;

    Stem Cell Transplantation Program,Division of Pediatric Hematology and Oncology,Manton Center for Orphan Disease Research,Children's Hospital Boston and Dana Farber Cancer Intitute,Boston,Massachusetts,02115,USA,Department of Biological Chemistry and Molecular Pharmacology,Harvard Medical School,Boston,Massachusetts,02115,USA,Harvard Stem Cell Institute,Cambridge,Massachusetts,02138,USA,Stem Cell Program,Children's Hospital Boston,Boston,Massachusetts,02115,USA;

    Department of Biology,Massachusetts Institute of Technology,Cambridge,Massachusetts,02142,USA,Whitehead Institute for Bionedical Research,Cambridge,Massachusetts,02142,USA;

    Department of Biology,Massachusetts Institute of Technology,Cambridge,Massachusetts,02142,USA,The Broad Institute of Harvard and Massachusetts Institute of Technology,Cambridge,Massachusetts,02142,USA,Department of Systems Biology,Harvard Medical School,Boston,Massachusetts,02115,USA;

    Harvard Stem Cell Institute,Cambridge,Massachusetts,02138,USA,Division of Hematology/Oncology,Children's Hospital,Harvard Medical School,Boston,Massachusetts,02115,USA,Department of Pediatric Oncology,Harvard Medical School,Boston,Massachusetts,02115,USA;

    Stem Cell Transplantation Program,Division of Pediatric Hematology and Oncology,Manton Center for Orphan Disease Research,Children's Hospital Boston and Dana Farber Cancer Intitute,Boston,Massachusetts,02115,USA,Department of Biological Chemistry and Molecular Pharmacology,Harvard Medical School,Boston,Massachusetts,02115,USA,Harvard Stem Cell Institute,Cambridge,Massachusetts,02138,USA,Stem Cell Program,Children's Hospital Boston,Boston,Massachusetts,02115,USA,Division of Hematology/Oncology,Children's Hospital,Harvard Medical School,Boston,Massachusetts,02115,USA,Division of Hematology,Brigham and Women's Hospital,Boston,Massachusetts,02115,USA,Howard Hughes Medical Institute,Chevy Chase,Maryland,20815,USA;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 02:54:05

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号